Subscribe by Email

About the Blog

The Active Ingredient features expert insights and commentary from leaders of ZS Associates' global pharmaceuticals practice.

Search by Topic

see all

How Cloud Tech Has Leveled the Pharma Field

Posted by Kapil Nayyar on Thu, Aug 23, 2018

A new business entering the competitive pharmaceuticals market faces a steep climb, so any innovation capable of creating a handhold is highly valuable. The evolution of cloud computing technology over the past decade has been a particularly favorable development for startups, offering them essential resources and capabilities that might otherwise be cost prohibitive. At a high level, cloud tech encompasses several benefits:

Read More

Topics: Big Pharma, Analytics, artificial intelligence, machine learning, pharma companies, REVO, cloud technology, Intercept Pharmaceuticals

Get More Out of Your Next Strategy Workshop

Posted by Jennifer Curtis on Mon, Apr 23, 2018

Malik Kaman co-wrote this blog post with Jennifer Curtis. 

Strategy workshops help organizations explore how their actions can drive market events and competitor responses. They’re an internal exercise for the organization to prepare, debate and challenge internal assumptions and to assess strategic choices. When executed effectively, the workshop will challenge participants to define clear strategic objectives, inspire lively debate and encourage the critical evaluation of a diverse list of ideas.

Read More

Topics: sales, marketing, Big Pharma, goals, Strategy, pharmaceuticals, competitive advantage, pharma manufacturer, strategy workshop

AI Will Usher in ‘Dramatic’ Changes to Pharma’s Commercial Model

Posted by Pratap Khedkar on Thu, Jan 18, 2018

This is the second post in a three-part series on artificial intelligence in healthcare. 

Artificial intelligence is poised to revolutionize the healthcare ecosystem. Providers are starting to apply AI in an effort to leverage patient data, therapy information and standards of care to make better treatment decisions. Payers are experimenting with AI to help with pre-authorization and claims adjudication. Whether or not the pharma industry is ready, AI is changing the way that pharma’s customers and stakeholders do business, thereby necessitating changes to pharma’s own commercial practices. And, according to my colleague John Piccone, those changes will be “dramatic.”

Read More

Topics: Big Pharma, healthcare ecosystem, AI, commercial strategy, artificial intelligence & pharma, pre-authorization, educate algorithms, treatment decisions, clinical decision support, claims, AI blog series

Is AI in Pharma Ready to Move From Hype to Hope?

Posted by Pratap Khedkar on Thu, Jan 11, 2018

This is the first post in a three-part series on artificial intelligence in healthcare. 

We encounter artificial intelligence platforms outside of healthcare on a regular basis, like when we ask Siri a question or view Netflix’s list of suggested films. However, within healthcare, and in the pharmaceutical industry specifically, AI has yet to live up to that level of success. In the near future, will AI become embedded in pharma R&D? Will it enable treatment decisions to be more automated—and more accurate? I recently called my colleague John Piccone, a ZS principal and advanced data science expert who previously led IBM Watson Health’s life sciences offerings, to discuss AI’s use both within pharma and throughout the healthcare ecosystem.

Read More

Topics: Big Pharma, Pratap Khedkar, R&D, artificial intelligence, automation tools, technology innovation, pharma companies, artificial intelligence & pharma, AI blog series

How Pharma Companies Are Engaging Patients as R&D Partners

Posted by Kristyn Feldman on Wed, Nov 08, 2017

Lisa Bance co-wrote this blog post with Kristyn Feldman.

This is the final post in a four-part series examining patient centricity within R&D.

To achieve true patient centricity in drug development, pharmaceutical companies need to follow four main principles: gain empathy for patients, uncover and meet patient needs, connect with patients and, finally, engage patients. By asking for and incorporating trial participant input at every level of R&D, the pharmaceutical industry can start to look at patients as true partners.

Read More

Topics: Big Pharma, Pharma, Patient Engagement, drug development, clinical trials, patient centricity, patient centricity in R&D, online patient network

Subscribe to The Active Ingredient


Subscribe to receive email notifications whenever new blog posts are published.